The tyrosine kinase inhibitor imatinib (STI571, Gleevec) is increasingly used in patients undergoing allogeneic transplantation for leukemia. However, little is known regarding its potential immunoregulatory effects. Here, we investigate the effect of 
Introduction
Imatinib mesylate (imatinib, STI571, Glivec® and Gleevec®) is a potent selective inhibitor of the tyrosine kinases (TKs) ABL, ARG, PDGFR α and β, and c-KIT. It has proven clinically efficacy in the treatment of malignancies characterized by constitutive activation of these TKs: chronic myeloid leukemia (CML), Philadelphia chromosome positive (Ph + ) acute lymphocytic leukemia (ALL), myleoproliferative disorders due to chromosomal rearrangements in the PDGF-R locus and gastrointestinal stromal tumors (GIST) with mutations in c-KIT. [1] [2] [3] [4] [5] Imatinib can induce reversible dose-dependent hematological side-effects, predominantly neutropenia and thrombocytopenia. 3, 6 In CML, this may in part be attributed to compromised normal hematopoiesis in addition to suppression of the bcr-abl positive clone that can dominate myelopoiesis. An additional mechanism may be inhibition of c-KIT in normal hematopoietic progenitor cells, which could account for the mild imatinibinduced myelosuppression observed in some patients with GIST. 2 However, these mechanisms are unlikely to account fully for the observed lymphopenia and hypogammaglobulinemia in CML patients on long-term imatinib therapy. In one study, 25% of CML patients on 400mg imatinib daily developed mild lymphopenia and a gradual reduction in serum immunoglobulin levels over 3 to 12 months of therapy. 7 Another recent study found an inhibitory effect of imatinib on the development of progenitor-cell derived dendritic cells (DCs) and demonstrated that DCs exposed to imatinib were less potent at inducing primary cytotoxic T-cell reactions against tumor antigens and recall antigens in vitro. 8 The molecular target of imatinib in DCs was not defined but a role for c-KIT inhibition appeared unlikely. This raises the possibility that imatinib could affect normal hematopoiesis and immune function through inhibition of additional TKs.
Effects of imatinib on T-cell activation and function have not been well defined.
However, TKs play a prominent role in T-cell receptor (TCR) signal transduction and thus it is conceivable that imatinib may interfere with this process. Physiological activation of T-lymphocytes in response to antigen is controlled by the TCR. 9, 10 The TCR For personal use only. on . by guest www.bloodjournal.org From 4 is comprised of α and β chains, the signaling subunits CD3 ε, γ and δ chains and TCR ζ.
TCR binding to cognate foreign peptide bound to major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APCs) triggers a signaling cascade that includes activation of the TKs LCK and FYN. 11 LCK phosphorylates the immunoreceptor tyrosine-based activation motifs (ITAM) on the TCR subunits to which ZAP70 is recruited. LCK activates ZAP70 which in turn phosphorylates the adaptor protein linker of activated T-cells (LAT) that serves as a key adaptor molecule controlling several important downstream activation events. ZAP70 is essential for TCR signal transduction, and ZAP70 deficiency has been shown to cause a severe immunodeficiency in humans and mice. 12, 13 The early TCR signaling events are enhanced by simultaneous engagement of the co-receptors CD8 and CD4 for MHC class I-and MHC class II-restricted antigens respectively, and, in some circumstances, by costimulatory molecules such as CD28 and integrin molecules. Functional consequences of T-cell activation include proliferation, cytokine production, degranulation and upregulation of activation markers such as CD25 and CD69. 14 The aim of this study was to investigate the effects of imatinib on TCR dependent T-cell activation. We show that imatinib reduces TCR-induced proliferation and activation at drug concentrations achieved in vivo and provide evidence that imatinib inhibits the most proximal signal transduction events through an inhibitory effect on the SRC-family TK LCK.
Materials and methods

Imatinib.
Imatinib mesylate was extracted from a commercially available 400mg imatinib mesylate tablet (Gleevec ® 10 mM stock and used at 1, 5, 10 or 25 µM. The biologic activity of extracted imatinib was tested in a cell death titration assay on BA/F3 bcr-abl and BA/F3 tel-abl cells. 4 Cell culture, stimulation and flow cytometry.
Jurkat T-cells and primary human T-cells from healthy blood donors were cultured in RPMI 1640 (Life Technologies Inc, Gaithersburg, MD), containing 10% FCS, 2mM Lglutamine, 50U/ml penicillin and 50µg/ml streptomycin (R10). Primary T-cells were purified by Ficoll-Hypaque density gradient centrifugation, followed by negative selection enrichment using magnetic beads coated with an antibody mix of CD19, CD14, CD56, CD16 and CD15 (Miltenyi Biotec, Auburn, CA). CD3
+ T-cells were 86% +/-8% pure as determined by flow cytometry. After overnight (ON) rest, the cells were incubated for 1h with or without imatinib and then stimulated with 50ng/ml anti-human CD3 antibody 12F6. 16 Phytohemagglutinin (PHA) and staphylococcal enterotoxin B (SEB) were obtained from Sigma (St. Louis, MO) and used at 5µg/ml, 10µg/ml respectively. DMSO diluted 1:10 in R10 was included as a negative control in functional assays. The activation level of the T-cells was evaluated by CD25-APC/CD69-PE expression analysis after 6h and 24h stimulation with 12F6 50ng/ml +/-imatinib.
Untreated T-cells served as negative controls in all experiments. PBMCs were collected from healthy volunteer donors under the NIH Department of Transfusion Medicine approved protocol no. 99-CC-0168 after informed consent was obtained.
All antibodies for flow cytometry were obtained from BD Pharmingen (San Diego, CA). T-cells (2x10 6 /ml) were stimulated with 12F6 50ng/ml +/-imatinib 1, 5, 10 or 25µM for 96h after 24h rest in R10 media, harvested and stained with annexin V-PE (incubation in the dark) and propidium iodide (PI). Apoptotic cells were defined by flow cytometry as PI negative and annexin V positive.
CFSE proliferation assay.
Purified human T-cells were suspended in phosphate buffered saline (PBS) (1x10 6 /ml) and labeled with the vital dye carboxyfluorescein diacetate succinimidyl ester (CFSE) at a final concentration of 0.25µM (Molecular Probes, Eugene, OR) for 7 minutes at 37 0 C.
After labeling, the cells were washed 3 times in FCS-rich medium and resuspended in R10 (2x10 6 cells/ml). After 24h rest, CFSE-labeled cells were preincubated with imatinib for 1h as indicated, and then cultured for 96h in the presence of 12F6 at 50ng/ml. for the ATP binding pocket was carried out using Blast search and sequences were aligned using Multialin software (http://prodes.toulouse.inra.fr/multalin/multalin.html).
Activation of epitope-specific CD8 + T-cells with CMV and EBV peptides.
23
Results
Imatinib inhibits T-cell proliferation induced by CD2 and TCR signaling.
To investigate the effect of imatinib on T-cell proliferation, we cultured human peripheral Fig. 1 E) and the average number of divisions completed ( Fig. 1 F) were significantly reduced. We focused our subsequent analyses on the TCR pathway and used 12F6 because of its ability to initiate TCR signaling directly and reproducibly.
Imatinib does not induce apoptosis in T-cells.
To investigate whether induction of apoptosis contributes to the reduced proliferation of imatinib treated T-cells, we measured apoptosis by staining with Annexin-V and propidium iodide (Fig. 2) . In unstimulated cells, imatinib at concentrations up to 25µM 
Imatinib decreases TCR-mediated T-cell activation.
We next investigated whether imatinib influenced TCR-dependent T-cell activation.
Upon activation, T-cells up-regulate expression of the cell surface molecules CD69 and CD25 14 and secrete cytokines including IL-2. We analyzed expression of CD69 and CD25 by flow cytometry on purified human peripheral blood T-cells at 6h and 24h
following activation by 12F6 with or without imatinib treatment (Fig. 3) . Expression of both markers in resting T-cells was low and was unaffected by imatinib. Up-regulation of the early T-cell activation marker CD69 was significantly inhibited by imatinib at concentrations as low as 1µM (p=0.0012) and completely abrogated at 25µM (Fig. 3) ; the mean inhibitory concentration (IC 50 ) was 7.3µM. The effect on CD69 was apparent 6h
after stimulation and persisted at 24h. In contrast, 12F6-induced expression of CD25 was only seen in a subset of T-cells, and became apparent only after 24h of incubation.
However, the inhibitory effect of imatinib on CD25 expression was comparable to its effect on CD69 with significant inhibition of CD25 up-regulation detectable at 1µM (p=0.005) and an IC 50 of 5.4µM. We also found comparable inhibition of CD69 upregulation in two donors stimulated simultaneously through both CD3/TCR and the costimulatory molecules CD28 and CD49d (data not shown).
Induction of IL-2 secretion in naive T-cells is dependent on signals mediated through
both the TCR and co-stimulatory receptors such as CD28, the receptor for the B7 family of co-stimulatory molecules, and CD49d, the receptor for integrin alpha. Therefore, we
For personal use only. on . by guest www.bloodjournal.org From stimulated T-cells with 12F6 in the presence or absence of activating antibodies against CD28 and CD49d and measured IL-2 in the cell culture supernatant 24h after induction.
The IL-2 produced under these conditions was almost completely suppressed by imatinib at 10µM (Fig. 4) .
CMV-and EBV-specific CD8
+ T-cell responses are suppressed by imatinib.
To test whether imatinib could also inhibit TCR stimulation by cognate antigen, we studied the responses of CD8 + T-cells specific for the HLA A2-restricted peptides CMV pp65 495-503 and EBV BMFLI 259-267 . [17] [18] [19] 24 These antigens are well characterized and clinically relevant; they are also typically immunodominant in the context of the respective infections. Initially, we used HLA-peptide tetramers, which allow direct visualization of antigen-specific T-lymphocytes, to identify donors with a detectable CMV-specific CD8 + T-cell population. We then stimulated purified T-cells from these donors with the CMV peptide pp65 495-503 and followed proliferation with the vital dye CFSE over a period of 4 days (2 donors) and 8 days (6 donors). Specific CD8 + T-cells from all 8 donors proliferated in response to the CMV peptide. In 4 out of 6 donors we found that imatinib reduced the proliferative response in a dose-dependent manner over 8 days (Fig. 5A) . Similar results were obtained in assays conducted over 4 days in the other 2 donors; representative data is shown in Fig. 5B . To confirm that this observation was generally applicable and not limited to the CD8 + T-cell response to CMV, we repeated the experiment in one donor with a CD8 + T-cell response to the EBV-derived peptide BMFLI 259-267 . We found comparable inhibition of specific CD8 + T-cell expansion in response to this antigen (Fig. 5C ). However, in the two donors with the largest CMVspecific CD8 + T-cell populations (1% and 2.9% of total CD8 + T-cells as defined by tetramer staining), imatinib was unable to inhibit expansion. This is in contrast to donors with CMV-specific CD8 + T-cell populations in the range of 0.2-0.6%. The basis for this difference is unclear but might relate to increased cross-stimulation in these large populations or to the relative distribution of central memory and effector CD8 + T-cells resulting in different thresholds for CD3/TCR-induced proliferation between these individuals.
25
For
Imatinib inhibits proximal signal transduction components of the CD3-TCR complex and decreases ZAP70 and LAT phosphorylation.
The effects of imatinib on T-cell proliferation and activation could be due to the inhibition of proximal signaling events mediated by the TCR, or due to a more global inhibition of cellular functions downstream of the initial signaling events. To investigate whether imatinib could inhibit TCR signal transduction we used the well-characterized Jurkat T-cell line. We stimulated Jurkat cells in the presence or absence of imatinib with 12F6 and OKT3, a second monoclonal antibody directed against CD3. Imatinib inhibited constitutive phosphorylation of proteins in the 120kDA and 65kDA range in the Jurkat Tcell line, especially at higher concentrations (Fig. 6A) . After 5minutes of stimulation with 12F6 or OKT3, there was a rapid and strong induction of phosphotyrosine proteins, most notably in the 70kDA and 35kDA range (Fig. 6A) . We hypothesized that these proteins might correspond to ZAP70, the essential TK for TCR signal transduction, and to LAT.
To determine the lowest imatinib concentration needed to inhibit activation of ZAP70 and LAT (linker for T-cell activation), we stimulated Jurkat cells exposed to increasing concentrations of imatinib with 12F6 and analyzed the amount of tyrosine phosphorylated ZAP70 and LAT by specific immunoprecipitation and immunoblotting ( Fig. 6B & 6C) . We found a dose-dependent decrease in the activation of these keysignaling molecules with a major reduction of tyrosine phosphorylation already evident at 5µM imatinib. Thus, the observed effects of imatinib on the proximal TCR signaling events correlate with the observed functional impairments of imatinib-treated normal human T-cells. 
Some cytoplasmic TKs involved in immunoreceptor signaling
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Imatinib inhibits LCK activity directly in vitro.
LCK is the first tyrosine kinase activated by TCR signaling and, as such, assumes a pivotal role in the transduction of extracellular recognition events into cellular effector functions. To confirm the predictions based on our sequence homology search, we tested the direct effect of imatinib on LCK in an in vitro tyrosine kinase assay. Imatinib inhibited LCK activity with an IC 50 of 0.6-0.8µM in two independent assays (R 2 0.99, Fig. 7B ), and almost complete inhibition was evident at 10µM imatinib.
Discussion
Imatinib is a potent tyrosine kinase inhibitor with impressive single agent activity that is now increasingly used as an adjunct in the allogeneic transplant setting for leukemia. We report here that imatinib inhibits primary T-cell proliferation and activation in response to TCR engagement in vitro. Importantly, imatinib also reduced expansion of primary cytotoxic T-cells in response to their cognate CMV or EBV antigen. These effects were dose-dependent with some inhibition of proliferation detectable at 1µM, which corresponds to the mean steady state level achieved after daily dosing with 400mg imatinib. Proliferation was almost completely suppressed at 10µM. No maximum tolerated dose has been established for imatinib and doses up to 500mg twice daily have been used in several studies. 3, 27 The mean peak plasma concentration after a single administration of 400mg is 4-5µM, but can reach 7.5µM at steady state with 400mg bid. 27 Our results extend a recent study that analyzed effects of imatinib on T-cell proliferation induced by PHA, which reported an IC 50 for proliferation of 3.9µM. We confirmed that inhibition of proliferation at these concentrations is not due to the induction of apoptosis.
In contrast to the study by Dietz et al. 28 however, we found that imatinib suppressed Tcell activation in addition to proliferation. The up-regulation of CD25 and CD69 was significantly inhibited by imatinib at 1µM with IC 50 concentrations of 5.4µM and 7.3µM
For personal use only. on November 16, 2017. by guest www.bloodjournal.org From 13 respectively, while no inhibition of these markers was detectable in the Dietz study. This discrepancy is likely due to the different signaling pathways studied. Dietz and coworkers stimulated the T-cells using PHA that activates CD2, while we used an anti-CD3 monoclonal antibody to stimulate the TCR, a more physiologic stimulus. Consistent with an inhibitory effect of imatinib on T-cell activation, we also found that imatinib reduced IL-2 production by activated T-cells.
Under conditions that reproduce physiologic stimulation of T-cells we found that imatinib inhibits proliferation of CMV specific CD8
+ T-cells stimulated by the clinically relevant HLA-A2 restricted CMV peptide pp65 [495] [496] [497] [498] [499] [500] [501] [502] [503] . To identify the CMV specific Tcell population we used an HLA-peptide tetramer as an affinity reagent. HLA-peptide tetramers have been widely applied to the study of human and murine immune responses and showed that the CD8 + cytotoxic T-lymphocyte (CTL) response to CMV was among the strongest immune responses studied. 29 The in vitro assays may not completely reproduce in vivo conditions, but the dose-dependent inhibition of CMV-specific proliferation argues for interference of imatinib with clinically important T-cell effector functions. Expansion of specific CD8 + CTL is important in clearance and control of viral infections. Several studies found an increased risk of CMV reactivation in patients with incomplete T-cell recovery after allogeneic stem cell transplantation and a reduced CD8 + CTL response to CMV correlates with recurrent CMV reactivation in the first 100 days after transplantation and predicts reduced disease-free survival. [30] [31] [32] [33] [34] [35] [36] [37] To test whether imatinib inhibits early TCR signaling directly, we analyzed tyrosine phosphorylation of the early key signal transduction components ZAP70 and LAT. In agreement with the inhibitory effects of imatinib on T-cell activation, we observed a dose-dependent reduction in ZAP70 and LAT activation. To investigate which kinases involved in immunoreceptor signaling might be sensitive to imatinib, we conducted a homology search with a consensus sequence derived from the ATP binding pocket of the known imatinib targets. One of the most homologous kinases that also share the critical threonine 315 (Thr315) residue is LCK. It is the first tyrosine kinase activated upon TCR engagement and initiates TCR signal transduction by activating ZAP70 and phosphorylating tyrosine residues on several of the TCR chains that recruit additional 26 ). However, structural differences in the activation loop of the two kinases likely underlie the much higher affinity of imatinib for ABL. 26 In an in vitro kinase assay, we confirmed that imatinib directly inhibits LCK activity with an IC 50 of 0.6-0.8µM. ZAP70 on the other hand is very unlikely to be a target of imatinib because its ATP binding pocket is less well conserved, and because it lacks the Thr315 residue present in ABL that is required for interaction with imatinib. This Thr315, when mutated in ABL or PDGF-R, confers clinical resistance to imatinib in CML and hypereosinophilia respectively, and abrogates the inhibitory effect of imatinib on the respective TKs.
38,39
Therefore, it appears that imatinib effects on TCR signaling are mediated through inhibition of LCK rather than ZAP70.
Imatinib affects TCR signal transduction and T-cell activation at concentrations achieved in human plasma. The IC 50 for most of these effects is in the range of the peak plasma In keeping with these findings, there are recent reports of imatinib-induced immunosuppressive effects in non-human primates as well as in patients on imatinib treatment. In a safety study, non-human primates treated for 39 weeks with imatinib showed an increased incidence of opportunistic infections. 43 Anecdotal case reports have described both viral infections 44, 45 and improvement in rheumatoid arthritis activity 46, 47 
